Xeme Biopharma Inc.

xeme biopharma inc. is clinical-stage company focused on developing therapeutic products in the area of active cancer immunotherapy (vaccines). this area of therapeutic cancer vaccines is expected by many oncology specialists to provide the next breakthrough in the treatment of cancer beyond the current approaches of surgery, radiation, chemotherapy and passive immunotherapy (monoclonal antibodies). xeme biopharma is focused on two integrated technology platforms: aggregon® and oncolipin. the aggregon® technology is used in the manufacture of oncoquest™-cll and oncoquest™-l, two innovative lead products of personalized (autologous) cancer vaccines for the treatment of leukemia and lymphoma, respectively. xeme’s unique, disruptive, and patented technology platform has the following competitive advantages: - indicated efficacy in previous clinical studies - very low cost of production / high margins - broad spectrum of potential clinical applications - personalized and off-the-s